您的位置: 首页 > 农业专利 > 详情页

UTILISATION DE DESAMINASES CLIVEES POUR LIMITER LA DESAMINATION HORS CIBLE NON DESIREE D'EDITION DE BASES
专利权人:
THE GENERAL HOSPITAL CORPORATION
发明人:
JOUNG, J. KEITH,ANGSTMAN, JAMES
申请号:
CA3063449
公开号:
CA3063449A1
申请日:
2018.05.25
申请国别(地区):
CA
年份:
2018
代理人:
摘要:
Described herein are methods and compositions for improving the genome-wide specificities of targeted base editing technologies. Herein, we describe dimeric base editing (BE) technologies that use split deaminases (sDA) that are functional when brought into close proximity to each other, one fused to a ZF and one to an nCas9-UGI protein comprising one or more UGIs, so as to limit the ability of the deaminase domain from deaminating at off-target ssDNA target sites independent of nCas9 R-loop formation. Thus, provided herein are fusion proteins comprising: (i) a first portion of a split deaminase ("sDAI") enzyme fused to a programmable DNA-binding domain; or (ii) a second portion of a split deaminase ("sDA2") fused to an nCas9 protein. The present invention also includes the vectors and cells comprising the vectors, as well as kits comprising the proteins and nucleic acids described herein.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充